Thursday, October 22, 2020

Med, Biotech & Pharma

Emerging Growth Medical, Biotechnology and Pharmaceutical Companies

The Top Diabetes Stocks for the remainder of 2020

Here is a company in the space that is finding its way onto the shelves of some major pharmacy retailers including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and online at Amazon.com (NASDAQ: AMZN) yet is still trading below a $30 million valuation.

Healthcare Stocks and the cost of Medical

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

Galectin Therapeutics (GALT) is Due for a COVID-19 Makeover

Galectin Therapeutics Inc. (NASDAQ: GALT) shot up close to 32.4% on Monday on record breaking volume of 4.9 million shares in anticipation of a long awaited investor conference call at 4PM ET on September 29th. In after hours trading the stock continues to climb to $4.20. GALT has one of the worst track records when it comes to shareholder communications with only 9 press releases this year, so it's easy to see why shareholders might be excited and speculating on news during the conference. GALT’s long term holders have pointed to outgoing CEO Harold Shlevin for the lack of communication while he focused on finishing the NASH phase 3 clinical trial design which took close to 2 years to complete.

The Covid-19 Vaccine is here, and the Winner Is

The goal in the US is to have a vaccine ready for at least some use by year end. Given the stringent approval process by the US FDA, it could be safe to say that another country may beat us to it. China and Russia have both made claims to this effect. But how safe will they be? Will there be any lasting side effects?

Food and Beverage Stocks in the Covid-19 Era

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

Healthcare to reduce the cost of medical – It’s not just for Humans

Marble Arch Research notes that PetVivo (OTCQB: PETV)achieved a major funding milestone last month, removing the main obstacle to its product commercialization goals. Commercial production of its disruptive osteoarthritis treatment device, Kush®, for canines and equines, a market we estimate is worth ~$3BN in the US alone, is due to commence in September 2020.

Covid-19 brings out a fitness craze and brings up Fitness stocks

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

Why VBI Vaccines (NASDAQ: VBIV) Could Be a Contrarian Investor’s Dream

While the list of those garnering the most attention read like the usual suspects, there’s probably one biotech firm you haven’t heard of, VBI Vaccines (NASDAQ:VBIV). While VBIV stock soared to multi-year highs around mid-July, shares have found themselves plummeting back to earth. As several now well-known vaccine companies have entered into late-stage clinical trials for their Covid-19 candidates, the other, smaller names have lost their luster.

Stocks to be in before 2021

Glucose Health, Inc. is an under-the-radar company whose GLUCODOWN® products are found in major national pharmacy chains including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and even online at Amazon.com (NASDAQ: AMZN) yet is still trading below a $20 million valuation.

The Best Social Distancing Stocks

Epazz, Inc. (OTC Pink: EPAZ) is currently sitting on its 100-day moving average and looks like it could rebound before hitting any resistance to about $.15 per share depending on how its Q3 comes in. If the stock could break resistance its next pivot is sitting at just under $.55 per share.

Latest News